TG THERAPEUTICS, INC. (TGTX) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does TG THERAPEUTICS, INC. Do?
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York. TG THERAPEUTICS, INC. (TGTX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael S. Weiss and employs approximately 290 people, headquartered in NEW YORK, New York. With a market capitalization of $5.4B, TGTX is one of the notable companies in the Healthcare sector.
TG THERAPEUTICS, INC. (TGTX) Stock Rating — Reduce (April 2026)
As of April 2026, TG THERAPEUTICS, INC. receives a Reduce rating with a composite score of 33.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TGTX ranks #2,076 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, TG THERAPEUTICS, INC. ranks #230 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
TGTX Stock Price and 52-Week Range
TG THERAPEUTICS, INC. (TGTX) currently trades at $33.65. The stock lost $0.98 (2.8%) in the most recent trading session. The 52-week high for TGTX is $46.48, which means the stock is currently trading -27.6% from its annual peak. The 52-week low is $25.28, putting the stock 33.1% above its annual trough. Recent trading volume was 1.4M shares, reflecting moderate market activity.
Is TGTX Overvalued or Undervalued? — Valuation Analysis
TG THERAPEUTICS, INC. (TGTX) carries a value factor score of 53/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 12.46x, compared to the Healthcare sector average of 23.63x — a discount of 47%. The price-to-book ratio stands at 8.23x, versus the sector average of 2.75x. The price-to-sales ratio is 10.50x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, TGTX trades at 62.54x EV/EBITDA, versus 6.34x for the sector.
Overall, TGTX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
TG THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score
TG THERAPEUTICS, INC. (TGTX) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 66.0%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 40.3% versus the sector average of -33.1%.
On a margin basis, TG THERAPEUTICS, INC. reports gross margins of 86.3%, compared to 71.5% for the sector. The operating margin is 16.2% (sector: -66.1%). Net profit margin stands at 67.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 120.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
TGTX Debt, Balance Sheet, and Financial Health
TG THERAPEUTICS, INC. has a debt-to-equity ratio of 64.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 4.10x, indicating strong short-term liquidity. Total debt on the balance sheet is $245M. Cash and equivalents stand at $74M.
TGTX has a beta of 0.57, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for TG THERAPEUTICS, INC. is 56/100, reflecting average volatility within the normal range for its sector.
TG THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, TG THERAPEUTICS, INC. reported revenue of $508M and earnings per share (EPS) of $3.10. Net income for the quarter was $428M. Gross margin was 86.3%. Operating income came in at $85M.
In FY 2025, TG THERAPEUTICS, INC. reported revenue of $616M and earnings per share (EPS) of $3.10. Net income for the quarter was $447M. Gross margin was 83.7%. Revenue grew 87.3% year-over-year compared to FY 2024. Operating income came in at $123M.
In Q3 2025, TG THERAPEUTICS, INC. reported revenue of $162M and earnings per share (EPS) of $2.69. Net income for the quarter was $391M. Gross margin was 82.6%. Revenue grew 92.8% year-over-year compared to Q3 2024. Operating income came in at $29M.
In Q2 2025, TG THERAPEUTICS, INC. reported revenue of $141M and earnings per share (EPS) of $0.19. Net income for the quarter was $28M. Gross margin was 86.6%. Revenue grew 92.1% year-over-year compared to Q2 2024. Operating income came in at $35M.
Over the past 8 quarters, TG THERAPEUTICS, INC. has demonstrated a growth trajectory, with revenue expanding from $73M to $508M. Investors analyzing TGTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
TGTX Dividend Yield and Income Analysis
TG THERAPEUTICS, INC. (TGTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
TGTX Momentum and Technical Analysis Profile
TG THERAPEUTICS, INC. (TGTX) has a momentum factor score of 34/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 67/100 reflects moderate short selling activity.
TGTX vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, TG THERAPEUTICS, INC. (TGTX) ranks #230 out of 838 stocks based on the Blank Capital composite score. This places TGTX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing TGTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TGTX vs S&P 500 (SPY) comparison to assess how TG THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.
TGTX Next Earnings Date
No upcoming earnings date has been announced for TG THERAPEUTICS, INC. (TGTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy TGTX? — Investment Thesis Summary
The quantitative profile for TG THERAPEUTICS, INC. suggests caution. The quality score of 10/100 flags below-average profitability. Momentum is weak at 34/100, a headwind for near-term performance.
In summary, TG THERAPEUTICS, INC. (TGTX) earns a Reduce rating with a composite score of 33.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TGTX stock.
Related Resources for TGTX Investors
Explore more research and tools: TGTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TGTX head-to-head with peers: TGTX vs AZN, TGTX vs SLGL, TGTX vs VMD.